A randomized, double-blind, placebo-controlled, dose-escalation study of intravenous adult human mesenchymal stem cells (prochymal) after acute myocardial infarction.

OBJECTIVES Our aim was to investigate the safety and efficacy of intravenous allogeneic human mesenchymal stem cells (hMSCs) in patients with myocardial infarction (MI). BACKGROUND Bone marrow-derived hMSCs may ameliorate consequences of MI, and have the advantages of preparation ease, allogeneic use due to immunoprivilege, capacity to home to injured tissue, and extensive pre-clinical support. METHODS We performed a double-blind, placebo-controlled, dose-ranging (0.5, 1.6, and 5 million cells/kg) safety trial of intravenous allogeneic hMSCs (Prochymal, Osiris Therapeutics, Inc., Baltimore, Maryland) in reperfused MI patients (n=53). The primary end point was incidence of treatment-emergent adverse events within 6 months. Ejection fraction and left ventricular volumes determined by echocardiography and magnetic resonance imaging were exploratory efficacy end points. RESULTS Adverse event rates were similar between the hMSC-treated (5.3 per patient) and placebo-treated (7.0 per patient) groups, and renal, hepatic, and hematologic laboratory indexes were not different. Ambulatory electrocardiogram monitoring demonstrated reduced ventricular tachycardia episodes (p=0.025), and pulmonary function testing demonstrated improved forced expiratory volume in 1 s (p=0.003) in the hMSC-treated patients. Global symptom score in all patients (p=0.027) and ejection fraction in the important subset of anterior MI patients were both significantly better in hMSCs versus placebo subjects. In the cardiac magnetic resonance imaging substudy, hMSC treatment, but not placebo, increased left ventricular ejection fraction and led to reverse remodeling. CONCLUSIONS Intravenous allogeneic hMSCs are safe in patients after acute MI. This trial provides pivotal safety and provisional efficacy data for an allogeneic bone marrow-derived stem cell in post-infarction patients. (Safety Study of Adult Mesenchymal Stem Cells [MSC] to Treat Acute Myocardial Infarction; NCT00114452).

[1]  R. Wahl,et al.  111In oxine labelled mesenchymal stem cell SPECT after intravenous administration in myocardial infarction , 2003, Nuclear medicine communications.

[2]  Joshua M Hare,et al.  Cardiac repair with intramyocardial injection of allogeneic mesenchymal stem cells after myocardial infarction. , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[3]  Roberto Bolli,et al.  Life and Death of Cardiac Stem Cells: A Paradigm Shift in Cardiac Biology , 2006, Circulation.

[4]  A. Ganser,et al.  Intracoronary Bone Marrow Cell Transfer After Myocardial Infarction: Eighteen Months’ Follow-Up Data From the Randomized, Controlled BOOST (BOne marrOw transfer to enhance ST-elevation infarct regeneration) Trial , 2006, Circulation.

[5]  S. Gerson,et al.  Allogeneic mesenchymal stem cell infusion for treatment of metachromatic leukodystrophy (MLD) and Hurler syndrome (MPS-IH) , 2002, Bone Marrow Transplantation.

[6]  R. D. de Boer,et al.  Early Beneficial Effects of Bone Marrow‐Derived Mesenchymal Stem Cells Overexpressing Akt on Cardiac Metabolism After Myocardial Infarction , 2009, Stem cells.

[7]  E. Seifried,et al.  Transcoronary Transplantation of Functionally Competent BMCs Is Associated With a Decrease in Natriuretic Peptide Serum Levels and Improved Survival of Patients With Chronic Postinfarction Heart Failure: Results of the TOPCARE-CHD Registry , 2007, Circulation research.

[8]  Anthony H. Aletras,et al.  Detecting Acute Coronary Syndrome in the Emergency Department With Cardiac Magnetic Resonance Imaging , 2003, Circulation.

[9]  M. Cheitlin.  Adult Bone Marrow–Derived Cells for Cardiac Repair: A Systematic Review and Meta-analysis , 2008 .

[10]  J. Hankinson,et al.  Standardisation of spirometry , 2005, European Respiratory Journal.

[11]  M Terrin,et al.  Reference spirometric values using techniques and equipment that meet ATS recommendations. , 2015, The American review of respiratory disease.

[12]  Arjun Deb,et al.  Secreted frizzled related protein 2 (Sfrp2) is the key Akt-mesenchymal stem cell-released paracrine factor mediating myocardial survival and repair , 2007, Proceedings of the National Academy of Sciences.

[13]  P. Pattany,et al.  Allogeneic mesenchymal stem cells restore cardiac function in chronic ischemic cardiomyopathy via trilineage differentiating capacity , 2009, Proceedings of the National Academy of Sciences.

[14]  N. Reichek,et al.  Recommendations for quantitation of the left ventricle by two-dimensional echocardiography. American Society of Echocardiography Committee on Standards, Subcommittee on Quantitation of Two-Dimensional Echocardiograms. , 1989, Journal of the American Society of Echocardiography : official publication of the American Society of Echocardiography.

[15]  J. Cigudosa,et al.  Spontaneous human adult stem cell transformation. , 2005, Cancer research.

[16]  A. Zeiher,et al.  Intracoronary bone marrow-derived progenitor cells in acute myocardial infarction. , 2006, The New England journal of medicine.

[17]  H. S. Mueller,et al.  The Thrombolysis in Myocardial Infarction (TIMI) trial. Phase I findings. , 1985, The New England journal of medicine.

[18]  H. Thiele,et al.  Intracoronary administration of bone marrow-derived progenitor cells improves left ventricular function in patients at risk for adverse remodeling after acute ST-segment elevation myocardial infarction: results of the Reinfusion of Enriched Progenitor cells And Infarct Remodeling in Acute Myocardial , 2009, American heart journal.

[19]  W. Vaughn,et al.  Mesenchymal Stem Cells Differentiate into an Endothelial Phenotype, Enhance Vascular Density, and Improve Heart Function in a Canine Chronic Ischemia Model , 2005, Circulation.

[20]  C M Gibson,et al.  Relationship of TIMI myocardial perfusion grade to mortality after administration of thrombolytic drugs. , 2000, Circulation.

[21]  Xin Chen,et al.  Chemokine stromal cell‐derived factor 1/CXCL12 increases homing of mesenchymal stem cells to injured myocardium and neovascularization following myocardial infarction , 2009, Chinese medical journal.

[22]  L. Muul,et al.  Isolated allogeneic bone marrow-derived mesenchymal cells engraft and stimulate growth in children with osteogenesis imperfecta: Implications for cell therapy of bone , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[23]  C. Bearzi,et al.  Stem cell niches in the adult mouse heart. , 2006, Proceedings of the National Academy of Sciences of the United States of America.

[24]  R. Kloner,et al.  Allogeneic Mesenchymal Stem Cell Transplantation in Postinfarcted Rat Myocardium: Short- and Long-Term Effects , 2005, Circulation.

[25]  S. E. Jacobsen,et al.  Potential risks of bone marrow cell transplantation into infarcted hearts. , 2007, Blood.

[26]  W. Ganz,et al.  The thrombolysis in myocardial infarction (TIMI) trial. , 1985, The New England journal of medicine.

[27]  ATS statement: guidelines for the six-minute walk test. , 2002, American journal of respiratory and critical care medicine.

[28]  J. Hare,et al.  Mechanisms of action of mesenchymal stem cells in cardiac repair: potential influences on the cardiac stem cell niche , 2007, Nature Clinical Practice Cardiovascular Medicine.

[29]  P. Doevendans,et al.  Bone marrow cell therapy after acute myocardial infarction: the HEBE trial in perspective, first results , 2008, Netherlands heart journal : monthly journal of the Netherlands Society of Cardiology and the Netherlands Heart Foundation.

[30]  Hanns-Ulrich Marschall,et al.  Mesenchymal Stem Cells for Treatment of Therapy-Resistant Graft-versus-Host Disease , 2006, Transplantation.

[31]  Joshua M Hare,et al.  Multimodality noninvasive imaging demonstrates in vivo cardiac regeneration after mesenchymal stem cell therapy. , 2006, Journal of the American College of Cardiology.

[32]  M. Greeley,et al.  Intra-coronary arterial injection of mesenchymal stromal cells and microinfarction in dogs , 2004, The Lancet.

[33]  F. Fernández‐Avilés,et al.  The consensus of the task force of the European Society of Cardiology concerning the clinical investigation of the use of autologous adult stem cells for repair of the heart. , 2006, European heart journal.

[34]  H. Drexler,et al.  Impact of intracoronary bone marrow cell transfer on diastolic function in patients after acute myocardial infarction: results from the BOOST trial. , 2006, European heart journal.

[35]  Giselle Chamberlain,et al.  Concise Review: Mesenchymal Stem Cells: Their Phenotype, Differentiation Capacity, Immunological Features, and Potential for Homing , 2007, Stem cells.

[36]  A. Boyle,et al.  Mesenchymal stem cells for cardiac regenerative therapy. , 2007, Handbook of experimental pharmacology.

[37]  Ergin Atalar,et al.  In Vivo Magnetic Resonance Imaging of Mesenchymal Stem Cells in Myocardial Infarction , 2003, Circulation.

[38]  P. Guldberg,et al.  Tumorigenic heterogeneity in cancer stem cells evolved from long-term cultures of telomerase-immortalized human mesenchymal stem cells. , 2005, Cancer research.

[39]  Robert L Wilensky,et al.  A quantitative, randomized study evaluating three methods of mesenchymal stem cell delivery following myocardial infarction. , 2006, European heart journal.

[40]  Joshua M. Hare,et al.  Is stem cell therapy ready for patients? Stem Cell Therapy for Cardiac Repair. Ready for the Next Step . , 2006, Circulation.